On the other hand, treatment with ESGA at increasing doses of 50, 100, and 200 mg/kg, failed to attenuate or reverse obesity and did not prevent increases in fat pad accumulation, glucose and insulin levels, HOMA-IR levels, or the circulatory levels of leptin in HFD-fed rats. The gene discussed is INS; the disease is obesity disorder.